Media & Press relations

Our latest press releases

November 03, 2026

Third-Quarter 2026 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ending September 30, 2026: Solid performance in Q3 2026 with +8% organic sales growth.

Discover more

Swipe for more

October 22, 2026

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE^® SPOTFIRE^® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics

bioMérieux's BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA).

Read more
October 19, 2026

WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response

bioMérieux, a world leader in in vitro diagnostics, announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the BIOFIRE® Global Fever Special Pathogens Panel, strengthening access to differential diagnostic testing in support of the ongoing Ebola Bundibugyo outbreak affecting the Democratic Republic of the Congo (DRC) and neighboring countries.

Read more
September 14, 2026

First-Half 2026 Results

bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26.

Read more